AGIO (Agios) Earnings per share for the last four quarters

Agios Pharmaceuticals Inc (AGIO) - corporate logo

Agios Pharmaceuticals (AGIO) is developing precision bioengineering to treat rare blood pathologies. The rolling year net income per share trend on this GURU.Markets chart confirms this trajectory, and the value of 9.00 shows the latest figure. This requires strict control over drug delivery; however, reliance on a single product and R&D risks are constraining the pace of reaching profitability.

AGIO agios.com Net earnings per share (EPS TTM) (02/11/2024 - 11/17/2026)

AGIO (Agios Pharmaceuticals): analytical breakdowns and indicator data

Fundamental company valuation:AGIO (Agios)
Core merchandise of Agios Corp

Strategic partnerships between Agios Pharmaceuticals (AGIO) and pharmaceutical behemoths and research centers specializing in rare diseases directly drive profit dynamics. By analyzing the trailing twelve months (TTM) earnings per share (EPS) growth rate, investors can track the percentage change in net income over a rolling year, enabling an assessment of commercialization efficiency and the impact of fundamental successes on the issuer's market capitalization.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Earnings per share for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Net earnings per one share for the last twelve months|SLNO - Earnings per share for the last twelve months|FOLD: Earnings per share for the last twelve months|ETNB: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx Corp|Rezolute Bio (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months lexpharma.com (LXRX)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS